Sexual health · 2026
Factors predicting STI-positive cervicitis and pelvic inflammatory disease, and implications on antibiotic use: a cross-sectional analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chawla Shreya, Varma Rick, Wong Arthur Ka Chun
Аннотация
BACKGROUND: Clinical diagnoses of cervicitis and pelvic inflammatory disease (PID) are often subjective, and not all are associated with sexually transmitted infections (STI). Presumptive treatment for these syndromes may lead to unnecessary antibiotics in those subsequently found to be STI-negative. We investigated patient and clinician characteristics associated with accurately diagnosing bacterial STI-positive cervicitis and PID. We quantified the amount of unnecessary antibiotics prescribed in STI-negative cases.
METHODS: A cross-sectional study of 243 cervicitis and 179 PID patients presenting to Sydney Sexual Health Centre between January 2020 and 2023 was conducted. Patient demographics, sexual behaviours, symptoms, examination, results and clinician type were extracted from electronic medical records.
RESULTS: A total of 70 cervicitis (28.8%) and 28 PID (15.6%) patients were bacterial-STI positive. Age <25 years (aOR 2.78, 95% CI 1.25-6.25, P < 0.001) was associated with bacterial STI-positive cervicitis; presence of endocervical mucopurulent discharge on examination (aOR 6.05, 95% CI 2.20-16.68, P < 0.001) and current use of contraception (aOR 7.69, 95% CI 2.13-25.00, P = 0.002) were associated with bacterial STI-positive PID. For cervicitis, there were 139 doxycycline, 11 azithromycin and 5 ceftriaxone courses that were given to STI-negative patients. For PID, there were 148 doxycycline, 7 azithromycin and 152 ceftriaxone courses that were given to STI-negative patients.
CONCLUSIONS: This study identified several characteristics that predicted STI-positive cervicitis and PID. However, none predicted STI-positivity with high degrees of confidence. Presumptive treatment leads to significant unnecessary antibiotic use, but ceftriaxone may have additional coverage beyond gonorrhoea. Rapid molecular point-of-care testing should be trialled to reduce unnecessary antibiotics for these syndromes - starting with cervicitis.
METHODS: A cross-sectional study of 243 cervicitis and 179 PID patients presenting to Sydney Sexual Health Centre between January 2020 and 2023 was conducted. Patient demographics, sexual behaviours, symptoms, examination, results and clinician type were extracted from electronic medical records.
RESULTS: A total of 70 cervicitis (28.8%) and 28 PID (15.6%) patients were bacterial-STI positive. Age <25 years (aOR 2.78, 95% CI 1.25-6.25, P < 0.001) was associated with bacterial STI-positive cervicitis; presence of endocervical mucopurulent discharge on examination (aOR 6.05, 95% CI 2.20-16.68, P < 0.001) and current use of contraception (aOR 7.69, 95% CI 2.13-25.00, P = 0.002) were associated with bacterial STI-positive PID. For cervicitis, there were 139 doxycycline, 11 azithromycin and 5 ceftriaxone courses that were given to STI-negative patients. For PID, there were 148 doxycycline, 7 azithromycin and 152 ceftriaxone courses that were given to STI-negative patients.
CONCLUSIONS: This study identified several characteristics that predicted STI-positive cervicitis and PID. However, none predicted STI-positivity with high degrees of confidence. Presumptive treatment leads to significant unnecessary antibiotic use, but ceftriaxone may have additional coverage beyond gonorrhoea. Rapid molecular point-of-care testing should be trialled to reduce unnecessary antibiotics for these syndromes - starting with cervicitis.